Among the systemic treatments that can be prescribed today, two types of novel agents are attractive and have been approved in many countries to alleviate the symptoms of AD; JAK inhibitors, such as baricitinib (anti-JAK1/2), abrocitinib (anti-JAK1), and upadacitinib (anti-JAK1), and anti-interleukin (IL) signaling antibody, such as dupilumab (anti-IL-4Rα), tralokinumab (anti-IL-13), and nemolizumab (anti-IL-31 Rα). Here, JAK1 is linked to Alzheimer disease.